Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled platform, Frobenius.
Evariste has raised $4.0M in total funding. The most recent round was Seed. The last funding was announced in January 2024.
Evariste is headquartered in London, United Kingdom.
Evariste discovers novel synthetic lethal oncology targets and designs small molecule therapeutics using its AI-enabled platform, Frobenius.
Evariste is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Evariste — Funding & Investors." VCBacked, January 1, 2024, https://www.vcbacked.co/company/evariste. Accessed August 1, 2026.
VCBacked. (2024). Evariste — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/evariste
{{cite web |title=Evariste — Funding & Investors |url=https://www.vcbacked.co/company/evariste |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated